MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia

Cell Reports

Volumn 18, Issue 2, 2017, Pages 482-495

  Kerry, Jon ^a   Godfrey, Laura ^a   Repapi, Emmanouela ^b   Tapia, Marta ^a   Blackledge, Neil P ^c   Ma, Helen ^d   Ballabio, Erica ^a   O'Byrne, Sorcha ^c   Ponthan, Frida ^e   Heidenreich, Olaf ^e   Roy, Anindita ^c   Roberts, Irene ^a,c   Konopleva, Marina ^d   Klose, Robert J ^c   Geng, Huimin ^f   Milne, Thomas A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

DOT1L; drug combination therapy; epigenetic spreading; epigenetic therapy; H3K79me2; leukemia; MLL; MLL AF4

Indexed keywords

1 [3 [[5 (4 AMINO 5 BROMO 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL) 3,4 DIHYDROXYTETRAHYDRO 2 FURFURYL](ISOPROPYL)AMINO]PROPYL] 3 (4 TERT BUTYLPHENYL)UREA; HISTONE H3; HISTONE H3K79; HISTONE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE DOT1L; METHIONINE; MIXED LINEAGE LEUKEMIA PROTEIN; MLL AF4 PROTEIN; PEPTIDES AND PROTEINS; PINOMETOSTAT; UNCLASSIFIED DRUG; VENETOCLAX; DOT1L PROTEIN, HUMAN; HISTONE; LENS EPITHELIUM-DERIVED GROWTH FACTOR; LYSINE; MEN1 PROTEIN, HUMAN; METHYLTRANSFERASE; MLL-AF4 FUSION PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN BINDING; SIGNAL PEPTIDE;

ARTICLE; BINDING SITE; CANCER PROGNOSIS; CHEMOSENSITIVITY; CHROMATIN; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; ENHANCER REGION; ENZYME INHIBITION; EPIGENETICS; FETUS; FUSION GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA; MLLAF4 GENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; WILD TYPE; ANTAGONISTS AND INHIBITORS; GENETICS; HUMAN GENOME; METABOLISM; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

BINDING SITES; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION REGULATION, LEUKEMIC; GENOME, HUMAN; HISTONES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA; LYSINE; METHYLTRANSFERASES; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS;

EID: 85009192374     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.12.054     Document Type: Article

References (40)

1. Bair, E., Tibshirani, R., Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol., 2, 2004, E108.
2. Ballabio, E., Milne, T.A., Molecular and epigenetic mechanisms of MLL in human leukemogenesis. Cancers (Basel) 4 (2012), 904–944.
3. Benayoun, B.A., Pollina, E.A., Ucar, D., Mahmoudi, S., Karra, K., Wong, E.D., Devarajan, K., Daugherty, A.C., Kundaje, A.B., Mancini, E., et al. H3K4me3 breadth is linked to cell identity and transcriptional consistency. Cell 158 (2014), 673–688.
4. Benito, J.M., Godfrey, L., Kojima, K., Hogdal, L., Wunderlich, M., Geng, H., Marzo, I., Harutyunyan, K.G., Golfman, L., North, P., et al. MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199. Cell Rep. 13 (2015), 2715–2727.
5. Bernt, K.M., Zhu, N., Sinha, A.U., Vempati, S., Faber, J., Krivtsov, A.V., Feng, Z., Punt, N., Daigle, A., Bullinger, L., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20 (2011), 66–78.
6. Birke, M., Schreiner, S., García-Cuéllar, M.P., Mahr, K., Titgemeyer, F., Slany, R.K., The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation. Nucleic Acids Res. 30 (2002), 958–965.
7. Biswas, D., Milne, T.A., Basrur, V., Kim, J., Elenitoba-Johnson, K.S., Allis, C.D., Roeder, R.G., Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Proc. Natl. Acad. Sci. USA 108 (2011), 15751–15756.
8. Blackledge, N.P., Long, H.K., Zhou, J.C., Kriaucionis, S., Patient, R., Klose, R.J., Bio-CAP: a versatile and highly sensitive technique to purify and characterise regions of non-methylated DNA. Nucleic Acids Res., 40, 2012, e32.
9. Blackledge, N.P., Farcas, A.M., Kondo, T., King, H.W., McGouran, J.F., Hanssen, L.L., Ito, S., Cooper, S., Kondo, K., Koseki, Y., et al. Variant PRC1 complex-dependent H2A ubiquitylation drives PRC2 recruitment and polycomb domain formation. Cell 157 (2014), 1445–1459.
10. Borkin, D., He, S., Miao, H., Kempinska, K., Pollock, J., Chase, J., Purohit, T., Malik, B., Zhao, T., Wang, J., et al. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell 27 (2015), 589–602.
11. Buenrostro, J.D., Giresi, P.G., Zaba, L.C., Chang, H.Y., Greenleaf, W.J., Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10 (2013), 1213–1218.
12. Caslini, C., Yang, Z., El-Osta, M., Milne, T.A., Slany, R.K., Hess, J.L., Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res. 67 (2007), 7275–7283.
13. Daigle, S.R., Olhava, E.J., Therkelsen, C.A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P.A., Allain, C.J., Klaus, C.R., Raimondi, A., Scott, M.P., et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122 (2013), 1017–1025.
14. Farcas, A.M., Blackledge, N.P., Sudbery, I., Long, H.K., McGouran, J.F., Rose, N.R., Lee, S., Sims, D., Cerase, A., Sheahan, T.W., et al. KDM2B links the polycomb repressive complex 1 (PRC1) to recognition of CpG islands. eLife, 1, 2012, e00205.
15. Garcia-Cuellar, M.P., Büttner, C., Bartenhagen, C., Dugas, M., Slany, R.K., Leukemogenic MLL-ENL fusions induce alternative chromatin states to drive a functionally dichotomous group of target genes. Cell Rep. 15 (2016), 310–322.
16. Geng, H., Brennan, S., Milne, T.A., Chen, W.Y., Li, Y., Hurtz, C., Kweon, S.M., Zickl, L., Shojaee, S., Neuberg, D., et al. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov. 2 (2012), 1004–1023.
17. Gilan, O., Lam, E.Y., Becher, I., Lugo, D., Cannizzaro, E., Joberty, G., Ward, A., Wiese, M., Fong, C.Y., Ftouni, S., et al. Functional interdependence of BRD4 and DOT1L in MLL leukemia. Nat. Struct. Mol. Biol. 23 (2016), 673–681.
18. Guenther, M.G., Lawton, L.N., Rozovskaia, T., Frampton, G.M., Levine, S.S., Volkert, T.L., Croce, C.M., Nakamura, T., Canaani, E., Young, R.A., Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 22 (2008), 3403–3408.
19. Harvey, R.C., Mullighan, C.G., Wang, X., Dobbin, K.K., Davidson, G.S., Bedrick, E.J., Chen, I.M., Atlas, S.R., Kang, H., Ar, K., et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 116 (2010), 4874–4884.
20. Jones, B., Su, H., Bhat, A., Lei, H., Bajko, J., Hevi, S., Baltus, G.A., Kadam, S., Zhai, H., Valdez, R., et al. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS Genet., 4, 2008, e1000190.
21. Krivtsov, A.V., Feng, Z., Lemieux, M.E., Faber, J., Vempati, S., Sinha, A.U., Xia, X., Jesneck, J., Bracken, A.P., Silverman, L.B., et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14 (2008), 355–368.
22. Li, B.E., Gan, T., Meyerson, M., Rabbitts, T.H., Ernst, P., Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells. Blood 122 (2013), 2039–2046.
23. Lin, S., Luo, R.T., Ptasinska, A., Kerry, J., Assi, S.A., Wunderlich, M., Imamura, T., Kaberlein, J.J., Rayes, A., Althoff, M.J., et al. Instructive role of MLL-fusion proteins revealed by a model of t(4;11) pro-B acute lymphoblastic leukemia. Cancer Cell 30 (2016), 737–749.
24. Long, H.K., Blackledge, N.P., Klose, R.J., ZF-CxxC domain-containing proteins, CpG islands and the chromatin connection. Biochem. Soc. Trans. 41 (2013), 727–740.
25. Lovén, J., Hoke, H.A., Lin, C.Y., Lau, A., Orlando, D.A., Vakoc, C.R., Bradner, J.E., Lee, T.I., Young, R.A., Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153 (2013), 320–334.
26. Meyer, C., Hofmann, J., Burmeister, T., Gröger, D., Park, T.S., Emerenciano, M., Pombo de Oliveira, M., Renneville, A., Villarese, P., Macintyre, E., et al. The MLL recombinome of acute leukemias in 2013. Leukemia 27 (2013), 2165–2176.
27. Milella, M., Estrov, Z., Kornblau, S.M., Carter, B.Z., Konopleva, M., Tari, A., Schober, W.D., Harris, D., Leysath, C.E., Lopez-Berestein, G., et al. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 99 (2002), 3461–3464.
28. Milne, T.A., Martin, M.E., Brock, H.W., Slany, R.K., Hess, J.L., Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res. 65 (2005), 11367–11374.
29. Milne, T.A., Kim, J., Wang, G.G., Stadler, S.C., Basrur, V., Whitcomb, S.J., Wang, Z., Ruthenburg, A.J., Elenitoba-Johnson, K.S., Roeder, R.G., Allis, C.D., Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol. Cell 38 (2010), 853–863.
30. Mueller, D., Bach, C., Zeisig, D., Garcia-Cuellar, M.P., Monroe, S., Sreekumar, A., Zhou, R., Nesvizhskii, A., Chinnaiyan, A., Hess, J.L., Slany, R.K., A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 110 (2007), 4445–4454.
31. Muntean, A.G., Tan, J., Sitwala, K., Huang, Y., Bronstein, J., Connelly, J.A., Basrur, V., Elenitoba-Johnson, K.S., Hess, J.L., The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 17 (2010), 609–621.
32. Okuda, H., Kawaguchi, M., Kanai, A., Matsui, H., Kawamura, T., Inaba, T., Kitabayashi, I., Yokoyama, A., MLL fusion proteins link transcriptional coactivators to previously active CpG-rich promoters. Nucleic Acids Res. 42 (2014), 4241–4256.
33. Pui, C.H., Carroll, W.L., Meshinchi, S., Arceci, R.J., Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J. Clin. Oncol. 29 (2011), 551–565.
34. Risner, L.E., Kuntimaddi, A., Lokken, A.A., Achille, N.J., Birch, N.W., Schoenfelt, K., Bushweller, J.H., Zeleznik-Le, N.J., Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia. J. Biol. Chem. 288 (2013), 29901–29910.
35. Whyte, W.A., Orlando, D.A., Hnisz, D., Abraham, B.J., Lin, C.Y., Kagey, M.H., Rahl, P.B., Lee, T.I., Young, R.A., Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153 (2013), 307–319.
36. Wilkinson, A.C., Ballabio, E., Geng, H., North, P., Tapia, M., Kerry, J., Biswas, D., Roeder, R.G., Allis, C.D., Melnick, A., et al. RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Rep. 3 (2013), 116–127.
37. Yokoyama, A., Cleary, M.L., Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 14 (2008), 36–46.
38. Yokoyama, A., Somervaille, T.C., Smith, K.S., Rozenblatt-Rosen, O., Meyerson, M., Cleary, M.L., The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123 (2005), 207–218.
39. Yokoyama, A., Lin, M., Naresh, A., Kitabayashi, I., Cleary, M.L., A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 17 (2010), 198–212.
40. Zhu, L., Li, Q., Wong, S.H., Huang, M., Klein, B.J., Shen, J., Ikenouye, L., Onishi, M., Schneidawind, D., Buechele, C., et al. ASH1L links histone H3 lysine 36 dimethylation to MLL leukemia. Cancer Discov. 6 (2016), 770–783.